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Abstract 
Background/aims: The views of people with inherited retinal disease are important to help 
develop health policy and plan services. This study aimed to record levels of understanding of 
and attitudes to genetic testing for inherited retinal disease, and views on the availability of 
testing. 
Methods: Telephone questionnaires comprising quantitative and qualitative items were 
completed with adults with inherited retinal disease. Participants were recruited via postal 
invitation (response rate 48%), approach at clinic or the newsletters of relevant charitable 
organisations. 
Results: Questionnaires were completed with 200 participants. Responses indicated that 
participants‟ perceived understanding of genetic testing for inherited retinal disease was 
variable. The majority (90%) considered testing to be good/very good and would be likely to 
undergo genetic testing (90%) if offered. Most supported the provision of diagnostic (97%) and 
predictive (92%) testing, but support was less strong for testing as part of reproductive 
planning. Most (87%) agreed with the statement that testing should be offered only after 
individual have received genetic counselling from a professional. Subgroup analyses revealed 
differences associated with participant age, gender, education level and ethnicity (p<.02). 
Participants reported a range of perceived benefits (e.g. family planning, access to treatment,) 
and risks (e.g. impact upon family relationships, emotional consequences). 
Conclusion: Adults with inherited retinal disease strongly support the provision of publicly 
funded genetic testing. Support was stronger for diagnostic and predictive testing than for 
testing as part of reproductive planning. 
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INTRODUCTION 
 Inherited retinal diseases are an important cause of visual disability, leading to loss of 
visual field (peripheral vision), visual acuity (detailed, central vision) or both. Individual 
conditions are rare and the most common conditions, retinitis pigmentosa (RP) and Stargardt 
disease occur in only 1:3,700 and 1:10,000 individuals respectively.
1, 2
  
 To date, almost 250 disease-causing genes have been identified or mapped. The number 
of different genes involved makes genetic testing difficult but not impossible. Using the 
phenotype and family history to direct testing, screening for common mutations or with the use 
of next generation sequencing, it is possible to identify a faulty gene or mutation in 40–70% of 
selected cases.
3, 4 
 The identification of the genetic basis of an inherited retinal disease has the potential to 
offer many advantages. It can provide a precise clinical diagnosis, confirm the condition is 
inherited and the pattern of inheritance, provide a more accurate guide to future visual 
function, assist marriage and family planning and may also allow patients to be added to 
disease registries, giving them early access to clinical trials and emerging treatments that are 
gene- or mutation-specific. Despite these potential benefits and support from clinicians and 
patient groups, the availability and uptake of genetic testing for inherited retinal diseases 
within the publicly funded National Health Service (NHS) are variable.
5
 This may be the result 
of several factors, including cost, perceived clinical utility, variations in the commissioning and 
provision of specialised eye genetic services and a lack of evidence of demand from service 
users. We have completed preliminary research into these issues involving a survey of 
delegates at a national patient conference.
6
 This study aimed to investigate these issues further 
by investigating perceived understanding of and attitudes to genetic testing in a larger sample 
of individuals with inherited retinal disease and exploring potential differences between 
subgroups. 
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MATERIALS AND METHODS 
Participants: Invitation letters were sent to patients who had previously attended eye clinics in 
Yorkshire. Participants were also recruited from the eye clinic or via newsletters of two 
national charities, RP Fighting Blindness and the Macular Society. At the time of recruitment, 
access to diagnostic genetic testing in a clinical laboratory was not routinely available locally. 
Patients aged over 16 years, with a clinical diagnosis of inherited retinal disease but without a 
significant hearing impairment were eligible. Invitation letters were available in English and 
Urdu and the study information leaflet and consent forms were available in print, electronic 
and Braille formats. Ethical approval was received from the Leeds (East) Research Ethics 
Committee (10/H1306/90) and informed consent was obtained from all participants. 
Questionnaire: Semi-structured, telephone questionnaires were conducted with participants. 
Demographic information was collected, together with both quantitative and qualitative data on 
the level of understanding of, attitudes to and the availability of genetic testing for inherited 
retinal disease. Three Likert scale items explored understanding (“Do you feel that you 
understand what a genetic test is?”), attitudes (“Based on what you know right now, do you 
consider genetic testing for inherited eye disease to be good or bad?”) and willingness to 
undergo genetic testing (“Based on what you know right now, how likely would you be to have 
a genetic test for inherited eye disease if offered tomorrow?”). All used a five-point scale, with 
1 indicating a strong negative response or level of support and 5 indicating a strong positive 
response. A further eight questions explored participants‟ support for the availability of genetic 
testing for inherited retinal disease in general and for testing in specific circumstances namely 
diagnostic testing, testing in children under 18 years, predictive testing, carrier status testing 
for reproductive planning, pre-implantation genetic diagnosis and pre-natal diagnosis. For 
these questions, the choice of responses was limited to “yes”, “not sure” or “no”. Responses to 
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questions were followed by prompts or further questions to clarify or expand the initial answer. 
Questionnaires typically lasted approximately 30 minutes, were conducted in English, Urdu, 
Punjabi or Mirpuri by TAW, BP or MA and recorded. 
 
Data analysis: Quantitative data were analysed for the whole sample and then according to 
each of seven, pre-determined subgroups: age (</≥50 years), sex, ethnicity (White 
British/other), highest educational level (up to GCSE or O level/College or higher), sight 
impairment certification status, parenting status (current or planned parent/no parenting plans) 
and the presence/absence of other affected family members. In addition, exploratory analyses 
revealed that participants with congenital conditions did not differ from those with acquired 
visual impairment in perceived understanding, attitude, nor the likelihood of undergoing testing 
(although numbers in the former group were small, precluding meaningful statistical 
comparisons). Differences in responses to Likert scale items were analysed using the Mann-
Whitney U test for independent groups. The subgroups were compared in their responses to the 
items concerning the availability of testing for different purposes. This analysis was conducted 
using Chi-square or Fisher‟s exact test, as appropriate. Where significant differences were 
observed, independence between subgroups was tested using Chi-square analysis. Due to the 
number of tests being conducted, a more stringent significance level of p<.02 was applied. 
Responses to open-ended questions were coded independently by two researchers (BP, TAW). 
Results were compared and differences resolved by consensus. The summarized statements, 
transcribed verbatim from the original recordings, were analyzed using a thematic approach, a 
common analytical method in this area,
7, 8
 and managed using NVivo8. Selected responses 
were chosen to illustrate the differing levels of understanding of genetic testing, attitudes to 
and support for genetic testing. 
RESULTS 
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The sample comprised 200 participants with a clinical diagnosis of inherited retinal disease. 
The majority (n=129) were recruited following postal invitation, for which the positive 
response rate was 48.1%. Other participants were recruited from clinic (n=41), newsletters 
(n=28) or via contact with affected relatives (n=2). There were 110 females (55%) and 
participants‟ median age was 50 years (range 18-84 years). Demographic data and the most 
common clinical diagnoses are presented in Table 1. 
Table 1: Participant demographic data 
Clinical diagnosis  
 Retinitis pigmentosa 90 (45%) 
 Stargardt disease 26 (13%) 
 Cone dystrophy 8 (4%) 
 Sorsby fundus dystrophy 6 (3%) 
 X-linked retinoschisis 5 (2.5%) 
 Best disease 4 (2%) 
 Choroideremia 4 (2%) 
 Leber congenital amaurosis 4 (2%) 
 Doyne honeycomb dystrophy 3 (1.5%) 
 Achromatopsia 2 (1%) 
 Oculo-cutaneous albinism 2 (1%) 
 Other or unspecified macular dystrophy 38 (19%) 
 Other generalised retinal dystrophy 8 (4%) 
   
Age range  
 ≥ 50 years 101 (50.5%) 
 < 50 years 99 (49.5%) 
   
Ethnicity  
 White British 167 (83.5%) 
 British Asian 31 (15.5%) 
 Mixed or other ethnic origin 2 (1%) 
   
Highest level of education  
 Primary school / no qualifications 36 (18%) 
 O or GCSE level 55 (27.5%) 
 College – diploma 39 (19.5%) 
 University degree 48 (24%) 
 Postgraduate 21 (10.5%) 
 Not answered 1 (0.5%) 
   
Sight impairment certification status  
 Severely sight impaired 111 (55.5%) 
 Sight impaired 36 (18%) 
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 Not certified 50 (25%) 
 Not known 3 (1.5%) 
   
Parenting status  
 Have or plan to have children 169 (84.5%) 
 Decision taken not to have children 31 (15.5%) 
   
Other affected family members  
 Other affected family members 110 (55%) 
  No other affected or known relatives  90 (45%) 
 
 
Responses to the Likert scale items are presented in Figure 1. Overall, the level of self-reported 
understanding about genetic testing was variable: 33% of the sample reported that they had no 
or little understanding, while 41% perceived themselves to have a high level of understanding 
(Figure 1; illustrative quotations are provided in Box 1). Participants educated to College-level 
or beyond reported a greater level of understanding than those with lower educational 
attainment (p=0.019). Attitudes towards genetic testing for inherited eye disease were largely 
positive: 90% considered testing to be good/very good. Responses to the third Likert scale item 
(concerning willingness to undergo testing) were similarly positive, with 90% being likely/very 
likely to undergo genetic testing. Responses to these items did not differ significantly across 
subgroups. Participant views of potential benefits and risks of genetic testing are illustrated in 
Boxes 2-3. 
 
Views on the general availability of genetic testing and its use for particular purposes were 
examined with a series of categorical items (Figure 2). The majority of participants supported 
diagnostic testing as a publicly funded service: 93% felt that the NHS should offer genetic 
testing for inherited retinal disease. Support was strong for both diagnostic (96.5%) and 
predictive testing (91.5%). Only 17% of participants thought that genetic testing should be 
limited to adults over the age of 18 years, while 87% felt that it should be offered only after the 
provision of information and genetic counselling. Support for genetic testing as part of 
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reproductive planning was mixed: 65% were in favour of carrier status testing, 52% supported 
pre-implantation genetic diagnosis and 45% were in favour of pre-natal diagnosis. 
 
Some subgroup differences emerged in responses to these items. First, age and sex effects were 
observed when asked whether genetic testing should be limited to those over 18. A Chi-square 
test indicated that responses were not equally distributed between younger and older 
participants (χ2 (2, N=200) =12.24, p=0.002). Inspection of the frequency data indicated that 
younger participants were more likely to disagree with the statement that testing should be 
limited to those over 18 years (80.2%) than older participants (57.6%). Males and females also 
differed in their views on this issue (χ2 (2, N=200) =7.75, p=0.020), with females more likely 
than males to agree with such an age limit (23.6% vs. 8.9%). To assess the independence of the 
age and sex effects, a further Chi-square test was conducted and the two variables were found 
to be independent of each other (χ2 (1, N=200) =1.02, p=0.324). 
 
Effects of age and education were observed in relation to the use of prenatal genetic testing. 
Here, younger participants were more likely to support the use of prenatal testing (χ2 (2, 
N=200) =7.16, p=0.021; 50.5% vs. 39.4%), although this result did not meet our stringent level 
of significance. Responses were not equally distributed between groups categorised by 
educational attainment (χ2 (2, N=199) =13.21, p=0.001). Those completing a higher level of 
education were more likely to oppose the option of prenatal testing (50.9% vs. 28.6%) and 
respondents with lower educational attainment reported a greater level of uncertainty around 
this issue (Not Sure: 22.0% vs. 8.3%.). The effects of age and education were also found to be 
independent (χ2 (1, N=199) =2.18, p=0.156). 
 
Finally, responses to the availability of carrier status testing were not equally distributed 
between ethnic groups (χ2 (2, N=200)=11.69, p=0.003). Frequency data indicated that 
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participants of British Asian, mixed or other ethnicity were more likely to support access to 
carrier status testing than White British participants (90.9% vs. 59.9%). 
 
There were no differences between subgroups according to sight impairment certification, 
parenting status, or the presence of other affected family members. 
 
DISCUSSION 
This study explored understanding of and attitudes to genetic testing for inherited retinal 
disease in a large sample of affected adults. The aim was to collect data to inform inherited 
retinal disease services, improve information provision and assess current demand for genetic 
testing. 
 
When participants were asked to self-rate their level of understanding of genetic testing for 
inherited retinal disease, a wide range of responses was obtained. The only subgroup difference 
in perceived understanding was due to education: those educated to College level or above 
reported a significantly greater understanding. In general, public understanding of genetic 
science appears to be variable.
9, 10
 Many people have difficulty explaining the meaning behind 
the concepts of „genetics‟ and „genes‟, despite being familiar with the terminology.10 One study 
found that females, younger participants (18-44 years) and those with higher educational 
attainment were more likely to possess greater knowledge in this field.
11
 However, unlike this 
research, these studies were all conducted with the general public. Further exploration of 
understanding within patient samples is warranted to assess whether knowledge is greater in 
those affected by genetic conditions. 
 
The majority of participants viewed genetic testing for inherited retinal disease very positively. 
Support was very strong support for the provision of publicly funded diagnostic and predictive 
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genetic testing. However, most participants were in favour of information provision and access 
to genetic counselling before genetic testing. These findings are consistent with existing 
research in similar patient groups.
6, 12-14
 Support was less strong for genetic testing as part of 
reproductive planning. The use of pre-implantation genetic diagnosis to achieve an unaffected 
pregnancy has been reported in cases of recessive Stargardt disease, severe RP and X-linked 
retinoschisis
4, 15
 and pre-natal testing has also been reported for Leber congenital amaurosis.
3
 
Sizeable proportions of the current sample supported the use of genetic testing for reproductive 
planning purposes: 65% of participants supported carrier status testing, and 52% and 47% 
supported pre-implantation and prenatal genetic testing for inherited retinal disease, 
respectively. Similar figures have been reported elsewhere.
4, 6
 
 
Participants‟ comments provided additional important information on attitudes to pre-
implantation and prenatal testing. While approximately half of the sample felt that these 
services should be available, they would not necessarily choose to utilise them themselves. 
This finding may help to explain the phenomenon of high hypothetical but low actual uptake of 
(predictive) genetic testing.
16
 This pattern has been consistently observed in populations 
affected by Huntington disease
17, 18
 which has been considered a model of understanding the 
attitudes towards (predictive) testing for late-onset conditions with no treatment or cure
19
 such 
as many inherited retinal diseases.
12
 Our research suggests that when planning genetic testing 
services, patient attitudes should be explored in depth. 
 
Of interest in our study was stronger support for carrier status testing and reproductive 
planning in British Asian participants. This may reflect greater awareness of the risk in 
communities in which inherited retinal disease is more common.
20
 For some participants, 
genetic status might be one of the considerations when arranging a marriage. Others have 
explored genetic testing issues in similar populations
21, 22
 who might be marginally more 
 12 
affected by autosomal recessive genetic conditions due to a proportion of consanguineous 
marriages. 
 
Several common themes emerged in describing the potential benefits of testing. Frequently 
cited benefits included greater understanding and knowledge about the genetic basis of the 
condition, as well as early access to emerging therapies. Participants also reported benefits to 
family members and future generations, as well as to society in general. They were often aware 
of limited personal benefit but felt that the information gained from testing may contribute to 
treatments of others in the future. 
 
Participants were also asked about potential negative consequences of genetic testing. Several 
suggestions were offered, although a substantial number of respondents reported that they did 
not consider there to be any drawbacks. Reported disadvantages included the potential impact 
upon family relationships (i.e. feelings of guilt from passing a condition on, or blame in those 
who have inherited it) and the potential for results to be used to terminate pregnancies or 
increase insurance premiums. A substantial number of participants felt anxiety about their 
future. Many had ethical considerations. Emotional consequences of a result were frequently 
mentioned as disadvantageous. Other studies provide context to this finding. Mezer et al.
12
 
reported emotional distress in 57% of affected adults and their family members when 
recollecting their own predictive testing as children. By contrast, an investigation of a large 
family undergoing testing for hereditary myocilin glaucoma found no adverse impacts of 
predictive testing, five years following initial counselling
23
 and a systematic review of various 
genetic conditions also showed no long-term sequelae either for carriers or non-carriers.
24
 
 
Some limitations of the study must be acknowledged. Our sample was self-selecting and it is 
therefore possible that participants were more motivated and held more favourable attitudes 
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towards genetic testing than those who were invited but opted not to participate. Due to the 
recruitment methods employed, it is also acknowledged that study participants were currently 
engaged with the healthcare system and/or voluntary organisations. Several participants 
pointed out that whereas they wanted to know and were accepting of their diagnosis, other 
family members were not, and preferred ignorance of their genetic status. It is therefore to be 
expected that they may hold views different to those held by the participants in our research. 
Nevertheless, strengths of the study include the large number of affected individuals, with a 
range of clinical diagnoses and demographic characteristics. 
 
Individuals with inherited retinal disease express strong support for the provision of genetic 
testing, particularly diagnostic and predictive testing. Most are aware of a number of possible 
benefits but not the potential negative consequences. There is a need for the provision of 
information, in a format accessible to those with visual impairment, and access to genetic 
counselling before testing and this would be in keeping with patients‟ expectation. Our results 
indicated that information may be most effectively targeted toward less educated individuals, 
who reported lower levels of understanding and greater uncertainty around prenatal testing. 
However, support for genetic testing for inherited retinal disease is not universal and many 
participants (typically those with a higher level of education) were in favour of access for 
others but not by themselves, particularly in relation to prenatal testing for reproductive 
planning.  
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Box 1: Understanding of genetic testing 
 
Understanding of testing 
The quantitative results (see Figure 1) showed that participants‟ perceptions of their 
understanding of genetic testing and what it involved was variable. This was further illustrated 
by their comments: 
 
“To be honest I don‟t have any idea…I don‟t really know what you do. I‟d probably find it 
interesting if I did know. Do you look at chromosomes?” [ID141] 
 
“Yes, it‟s presumably to try and find out about the genes that cause the hereditary problem” 
[ID195] 
 
“I‟ve had a blood test. I‟ve had eye tests and all sorts. I‟m not sure I‟ve ever had a genetic test” 
[ID182] 
 
Several participants expressed uncertainty about the technical terms involved and would have 
appreciated a simplified explanation: 
 
“Always big words, tend to baffle normal people don‟t they?... It would be better to sort of 
understand it better in layman‟s terms” [ID012] 
 
A lack of understanding was often not a concern however, with many participants content with 
their current level of knowledge: 
 
“They did discuss things like that [autosomal dominant, recessive etc.] but I don‟t know huge 
amount about…er, genetic testing” 
 
Interviewer: What more would you like to know? 
“Nothing really” [ID089] 
 
 
Box 2: Advantages of genetic testing 
 
Advantages/benefits of genetic testing 
All participants were asked to outline what they considered to be the benefits of genetic testing 
for inherited retinal disease, and all were able to provide examples, including those who were 
not particularly in favour of being tested themselves. 
 
A common response was that testing would provide additional information, which may be 
beneficial for multiple reasons. For example, it might confirm a diagnosis, lead to further 
treatment options or aid understanding and remove uncertainty. For others, even if it didn‟t 
result in new treatments, the basic act of gaining knowledge was beneficial. 
 
“Information is power, if people know what‟s going on then they‟re actually in a position to try 
to do something about it and it stands to … increase whatever options are available, whatever 
treatments are out there” [ID108] 
 
“I‟d have more understanding and less fear in dealing with the disease” [ID030] 
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“…definitely a good thing…the more you know the better” [ID145] 
 
While participants understood that there were no curative treatments presently available, many 
expressed the view that genetic testing might help them in the future if and when new 
treatments became available: 
 
“If it means you‟re a candidate for gene therapy or something, then that is a good thing…you 
want to be first in the queue if it does happen” [ID205] 
 
Or if not them personally, then future generations: 
 
“[I]t might not help me at my age, but if it helps people like my daughter or younger people, if 
it‟s got some sort of cure or prevention for the future then that‟s obviously going to be good 
isn‟t it?” [ID051] 
 
Many participants felt that genetic testing could prove helpful when considering reproductive 
options as it would indicate the likelihood of children being affected. 
 
“It‟s extra information. It can help clarify for people if they are thinking about having a family 
what the possible risks are for their children. It may at some point be able to give people a 
more definite diagnosis and a clearer prognosis” [ID205] 
 
 
 
Box 3: Disadvantages of genetic testing and attitudes depending on circumstances 
 
Attitudes depending on circumstances 
 
While the majority of participants were in favour of testing being available, several reported 
that they wouldn‟t necessarily find it useful themselves. Its utility may relate to being at a 
particular stage of life, and outside of this it may not provide any noticeable benefit: 
 
“I don‟t know how you could use the information to be honest. I suppose the only way it‟s 
beneficial is if…you actually are in a relationship with someone…and wanting to have 
children…Apart from that I can‟t see it being of any use to me whatever” [ID206] 
 
Another participant explained that because of the potential significance of the result upon 
reproductive options, they would only want to have a test when they were in a couple and 
could receive the information together: 
 
“I wouldn‟t want [a genetic test]…until I was at the point where I was beginning to think about 
starting a family…it‟s a challenging thing to explain to a partner and I‟d actually rather go 
through it…with that individual, rather than knowing the result now and having the 
responsibility of making them aware of it” [ID205] 
 
A number of participants also believed that it was important to provide genetic testing to 
identify potential carriers, use in selecting the embryos and prenatal diagnosis but they 
themselves would not use it: 
 
“I think it should be available as a choice. Wouldn‟t be one I would go for but I think it can be 
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for other people to choose.” [ID205] 
 
 
Disadvantages/negative aspects of testing 
 
While many participants stated that they could not think of any disadvantage of genetic testing 
for inherited retinal disease, several negative aspects were suggested. For many, the emotional 
impact of receiving bad news was the main disadvantage of testing (although this may be 
transient): 
 
“I would be an emotional wreck for a while until I got my head around it” [ID107] 
 
Another disadvantage frequently cited was the potential impact of the results upon family 
relationships. Two parents who had undergone genetic testing described the impact of 
receiving confirmation that their condition had been passed to their children: 
 
“I found it very hard to deal with it. I was getting the bad news along with my daughter and I 
went out on a guilt trip because I had passed it on” [ID052] 
 
“It‟s an awful thought actually, to know that you‟ve passed it on… I know people say it 
could‟ve been something worse, but…” [ID103] 
 
Others raised the possibility of children blaming their parents: 
 
“Obviously your parents…I‟m not into this blaming…whose fault it was or anything, just to 
find out where it‟s come from… That‟s probably the negative…you end up…blaming 
somebody for…what you‟ve got…the disease you‟ve got” [ID014] 
 
 
Many participants raised the issue of eugenics and genetic testing being used as a rationale for 
treating individuals differently. For example, 
 
“I wouldn‟t want to use it for selective breeding. My view is that everybody is equal…and 
everybody‟s life is of value. So I wouldn‟t want…genetic testing to be used to…treat some 
people as of lower value…than others” [ID073] 
 
Issues concerning insurance were also frequently reported: 
 
“It would worry me greatly if insurance companies get access to the information and could 
adjust their premiums by what comes out of a genetic test. That‟s the bad side of it I think” 
[ID170] 
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Figure legends 
 
Figure 1 Participant understanding of, attitude to, and willingness to undergo genetic testing 
for inherited retinal disease 
 
Figure 2 Participant views on the general availability of genetic testing and its use for 
particular purposes 
